Advertisement
Drug Discovery
Subscribe to Drug Discovery

The Lead

AbbVie Announces Results for HS Treatment

October 17, 2014 1:21 pm | News | Comments

AbbVie announced new results from PIONEER 2, a pivotal Phase 3 study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. Read more...

UCSF, CDRD Sign Drug Development Agreement

October 17, 2014 1:06 pm | News | Comments

UCSFo and CDRD, a non-profit drug development...

Pharmacyclics' Non-Chemo Treatment Approved in Europe

October 17, 2014 10:54 am | News | Comments

Pharmacyclics Inc. announced that the European...

A Novel Approach to Alzheimer’s Disease

October 17, 2014 9:57 am | by Daniel L. Alkon, M.D.,Chief Scientific Officer, Neurotrope Inc. and Toyota Chair in Neurodegenerative Disease, Scientific Director and Professor, Blanchette Rockefeller Neurosciences Institute | Articles | Comments

Alzheimer's disease (AD) afflicts more than 5...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Big Step in Battling Bladder Cancer

October 16, 2014 3:06 pm | News | Comments

The millions of people worldwide who suffer from the painful bladder disease known as interstitial cystitis (IC) may soon have a better, long-term treatment option, thanks to a controlled-release, implantable device invented by MIT researchers. Read more...

Big Step in Battling Bladder Disease

October 16, 2014 1:33 pm | News | Comments

Novel device that stays in the bladder and slowly releases drugs sells to pharmaceutical giant. Read more...                                                             

Personalized Cellular Therapy Achieves Remission in Leukemia Patients

October 16, 2014 12:36 pm | News | Comments

Ninety percent of children and adults with ALL who had relapsed multiple times or failed to respond to standard therapies went into remission after receiving an investigational personalized cellular therapy, CTL019, developed at the Perelman School of Medicine at the University of Pennsylvania. Read more...

Advertisement

Moderna, Sweden Universities Collaborate on Drug Discovery

October 16, 2014 10:48 am | News | Comments

Moderna Therapeutics announced a strategic, long-term collaboration with Karolinska Institutet (KI) and Karolinska University Hospital (KUH) for the discovery and development of innovative drugs using Moderna's messenger RNA (mRNA) Therapeutics technology. mRNA Therapeutics(TM) enable the in vivo production of both intracellular proteins and secreted proteins. Read more...

Study Finds Neurons "Fine Tune" At Genetic Level

October 15, 2014 1:16 pm | News | Comments

Neurons are electrically charged cells in the nervous system that interpret and transmit information using electrical and chemical signals. A neuron’s electrical charge is determined by the flow of ions – charged atoms – in and out of the cell through pores, called ion channels. Read more...

Eisai's Thyroid Cancer Drug Gets FDA Priority Review

October 15, 2014 10:45 am | News | Comments

Eisai Inc. announced that the FDA has accepted for review the NDA for its in-house developed agent lenvatinib mesylate as a treatment for progressive RAI-refractory DTC and granted the NDA Priority Review status. Read more...

Selecta, JDRF, Sanofi Collaborate on SVP Immunotherapy for Type 1

October 15, 2014 10:31 am | News | Comments

Selecta Biosciences and JDRF, announced that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop an SVP immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. Read more...

Medtronic Begins Study of First Predictive Low Glucose Management Technology

October 14, 2014 1:39 pm | News | Comments

Medtronic Inc. announced that the first patients have been enrolled in an investigational device exemption (IDE) study of its breakthrough Predictive Low Glucose Management (PLGM) technology, marking a critical step toward development of an artificial pancreas in the U.S. market. Read more...

Advertisement

Rats of New York and The Diseases They Carry

October 14, 2014 12:29 pm | News | Comments

In the first study to look at would-be diseases carried by New York City rats, scientists at the Center for Infection and Immunity at Columbia University's Mailman School of Public Health identified bacterial pathogens, including E. coli, Salmonella, and C. difficile, that cause mild to life-threatening gastroenteritis in people. Read more...

Biologists Find Gene That Could Stop Tumors in Their Tracks

October 14, 2014 12:21 pm | News | Comments

The dirt in your backyard may hold the key to isolating cancerous tumors and to potential new treatments for a host of cancers. Read more...                                         

Astellas Collaborates with Harvard for Retinal Degeneration Treatment

October 14, 2014 12:13 pm | News | Comments

Astellas Pharma Inc. announced a research collaboration with an investigator at Harvard focused on discovering the pathologic mechanism for retinitis pigmentosa and identification of new therapeutic targets. Read more...

Rare Genetic Disease Protects Against Bipolar Disorder

October 14, 2014 12:01 pm | News | Comments

A team of scientists led by researchers at the UMass Medical School and UMMSM have identified what is likely a key genetic pathway underlying bipolar disorder, a breakthrough that could lead to better drugs for treating bipolar affective disorder, as well as depression and other related mood disorders. Read more...

C3BS Enrolls Patients in Switzerland in its Phase 3 Clinical Trial Chart-1

October 14, 2014 10:39 am | News | Comments

C3BS, a leader in the discovery and development of regenerative, protective and reconstructive therapies, announced it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase 3 trial for C-Cure in Switzerland. Read more...

Advertisement

Chemical Derived from Broccoli Sprouts Shows Promise in Treating Autism

October 14, 2014 10:27 am | News | Comments

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs). Read more...

Researchers Treat Pulmonary Hypertension Through the Leaves of Plants

October 14, 2014 10:18 am | News | Comments

Researchers at the University of Pennsylvania and the University of Florida have identified a drug that can be used to treat pulmonary hypertension, a disease for which few therapy options exist. Read more...                            

Scientists Link ALS Progression to Increased Protein Instability

October 14, 2014 10:09 am | News | Comments

A new study by scientists from The Scripps Research Institute (TSRI), Lawrence Berkeley National Laboratory (Berkeley Lab) and other institutions suggests a cause of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Read more...

New Cancer Drug to Begin Trials in Multiple Myeloma Patients

October 13, 2014 3:11 pm | News | Comments

Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. Read more...                            

Greater Rates of Mitochondrial Mutations in Children Born to Older Mothers

October 13, 2014 2:54 pm | News | Comments

The discovery of a "maternal age effect" by a team of Penn State scientists that could be used to predict the accumulation of mitochondrial DNA mutations in maternal egg cells -- and the transmission of these mutations to children -- could provide valuable insights for genetic counseling. Read more... 

Pfizer Gets FDA Acceptance of Palbociclib

October 13, 2014 2:35 pm | News | Comments

Pfizer Inc. announced the New Drug Application (NDA) for palbociclib has been accepted for filing and granted Priority Review by the United States Food and Drug Administration (FDA). Read more...                                

BMS, Pharmacyclics and Janssen Collaborate on Non-Hodgkin Lymphoma Drug

October 13, 2014 2:25 pm | News | Comments

Bristol-Myers Squibb Company, Pharmacyclics Inc., and Janssen Research & Development LLC announced they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Imbruvica. Read more...

Scientists Characterize a New Tumor Syndrome

October 13, 2014 11:08 am | News | Comments

Scientists at the Luxembourg Center for Systems Biomedicine (LCSB) of the University of Luxembourg have published their findings that mutations in a gene known as “ARMC5” promote the growth of benign tumors in the adrenal glands and on the meninges: ARMC5 appears to belong to the group of so-called tumour suppressor gene. Read more...

Concert Pharmaceuticals' Spasticity Drug Gets Positive Reviews

October 13, 2014 10:54 am | News | Comments

Concert Pharmaceuticals Inc. announced Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. Read more...                        

FDA Approves Drug for Chemo-Associated Nausea, Vomiting

October 13, 2014 10:10 am | News | Comments

Helsinn Group and Eisai Inc. announced that the FDA approved Akynzeo for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy Read more...                

FDA Approves First Drug-Coated Angioplasty Balloon Catheter for PAD

October 10, 2014 3:23 pm | News | Comments

The U.S. Food and Drug Administration approved the Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB). Read more...                              

Gilead Sciences' Once-Daily Hepatitis C Drug Approved by FDA

October 10, 2014 3:02 pm | News | Comments

Gilead Sciences, Inc. announced that the U.S. FDA has approved Harvoni (ledipasvir 90 mg/sofosbuvir 400 mg), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading